Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South Korea Type 1 Diabetes Treatment Market

ID: MRFR/HC/49464-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026

South Korea Type 1 Diabetes Treatment Market Research Report: By Treatment Type (Insulin Therapy, Continuous Glucose Monitoring, Insulin Pump Therapy, Immunotherapy), By Route of Administration (Subcutaneous, Intravenous, Inhalation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), andBy Age Group (Children, Adolescents, Adults)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South Korea Type 1 Diabetes Treatment Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 South Korea Type 1 Diabetes Treatment Market, BY Treatment Type (USD Billion)
      1. 4.1.1 Insulin Therapy
      2. 4.1.2 Continuous Glucose Monitoring
      3. 4.1.3 Insulin Pumps
      4. 4.1.4 Diabetes Management Software
    2. 4.2 South Korea Type 1 Diabetes Treatment Market, BY Patient Age Group (USD Billion)
      1. 4.2.1 Children
      2. 4.2.2 Adolescents
      3. 4.2.3 Adults
      4. 4.2.4 Elderly
    3. 4.3 South Korea Type 1 Diabetes Treatment Market, BY Administration Route (USD Billion)
      1. 4.3.1 Subcutaneous Injection
      2. 4.3.2 Intravenous Injection
      3. 4.3.3 Inhalation
      4. 4.3.4 Transdermal
    4. 4.4 South Korea Type 1 Diabetes Treatment Market, BY Healthcare Setting (USD Billion)
      1. 4.4.1 Hospitals
      2. 4.4.2 Clinics
      3. 4.4.3 Home Care
      4. 4.4.4 Telehealth
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the South Korea Type 1 Diabetes Treatment Market
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the South Korea Type 1 Diabetes Treatment Market
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novo Nordisk (DK)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sanofi (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boehringer Ingelheim (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Roche (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Abbott (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Eli Lilly (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Johnson & Johnson (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Dexcom (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 SOUTH KOREA MARKET ANALYSIS BY PATIENT AGE GROUP
    4. 6.4 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    5. 6.5 SOUTH KOREA MARKET ANALYSIS BY HEALTHCARE SETTING
    6. 6.6 KEY BUYING CRITERIA OF SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET
    9. 6.9 DRIVERS IMPACT ANALYSIS: SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET
    11. 6.11 SUPPLY / VALUE CHAIN: SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET
    12. 6.12 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY PATIENT AGE GROUP, 2024 (% SHARE)
    15. 6.15 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Billion)
    16. 6.16 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    17. 6.17 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
    18. 6.18 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY HEALTHCARE SETTING, 2024 (% SHARE)
    19. 6.19 SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Billion)
      2. 7.2.2 BY PATIENT AGE GROUP, 2026-2035 (USD Billion)
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
      4. 7.2.4 BY HEALTHCARE SETTING, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South Korea Type 1 Diabetes Treatment Market Segmentation

South Korea Type 1 Diabetes Treatment Market By Treatment Type (USD Billion, 2022-2035)

  • Insulin Therapy
  • Continuous Glucose Monitoring
  • Insulin Pumps
  • Diabetes Management Software

South Korea Type 1 Diabetes Treatment Market By Patient Age Group (USD Billion, 2022-2035)

  • Children
  • Adolescents
  • Adults
  • Elderly

South Korea Type 1 Diabetes Treatment Market By Administration Route (USD Billion, 2022-2035)

  • Subcutaneous Injection
  • Intravenous Injection
  • Inhalation
  • Transdermal

South Korea Type 1 Diabetes Treatment Market By Healthcare Setting (USD Billion, 2022-2035)

  • Hospitals
  • Clinics
  • Home Care
  • Telehealth

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions